Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:UCB
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:CEO |
Stephen J. Farr
|
| gptkbp:focusesOn |
rare diseases
central nervous system disorders |
| gptkbp:foundedIn |
2006
|
| gptkbp:founder |
Roger Hawley
Stephen J. Farr |
| gptkbp:headquartersLocation |
gptkb:Emeryville,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zogenix
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
Fintepla
Sumavel DosePro |
| gptkbp:stockSymbol |
ZGNX
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.zogenix.com
|
| gptkbp:bfsParent |
gptkb:CARIN_Alliance
gptkb:Zohydro_ER gptkb:Sorrento_Mesa |
| gptkbp:bfsLayer |
8
|